RejuvaKnee
Commercial- Indications
- Meniscus repair
Company intelligence / Profile preview
Regenity has over 25 years of experience developing and commercializing bioresorbable implants for soft and hard tissue regeneration. Its portfolio includes more than 71 product lines, with several FDA-cleared devices such as RejuvaKnee™ for meniscal repair and DermiSphere hDRT for full-thickness wound healing. The company is a global leader in contract development/manufacturing of regenerative medical devices, supplying over four million units annually to clients in more than 86 countries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regenity Biosciences.